医学
安慰剂
内科学
临床研究阶段
肿瘤科
串联
护理标准
相(物质)
化疗
临床试验
癌症研究
药理学
癌症
药代动力学
药品
阿霉素
作者
Pau Montesinos,Rebeca Rodríguez‐Veiga,Juan Bergua,Lorenzo Algarra,Carmen Botella,Eduardo Rodríguez‐Arbolí,Teresa Bernal,Mar Tormo,María Calbacho,Olga Salamero,Josefina Serrano,Víctor Noriega,Juan Antonio López,Susana Vives,José Luis López Lorenzo,Mercedes Colorado,María‐Belén Vídriales,Raimundo García Boyero,María Teresa Olave,Pilar Herrera
摘要
The addition of quizartinib to standard chemotherapy was associated with significantly longer EFS and OS than placebo in patients with ND FLT3-ITD-negative AML.
科研通智能强力驱动
Strongly Powered by AbleSci AI